1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Patrys Limited
  6. News
  7. Summary
    PAB   AU000000PAB9

PATRYS LIMITED

(PAB)
Delayed Australian Stock Exchange  -  02:10 2022-06-28 am EDT
0.0200 AUD   -9.09%
06/14Patrys Identifies New Mechanism of Action for Anti-Cancer Antibody
MT
06/03Patrys Secures Grant Funding to Develop Brain Cancer Drug
MT
04/27PATRYS : Appendix 4C - Quarterly - 31 March 2022
PU
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Patrys : ADC Deals Making Headlines

02/07/2022 | 05:51pm EDT

Late last year, Patrys announced new data from a preclinical study that demonstrated potential for using our deoxymab antibodies as targeting agents in ADCs. This was a promising development, and one which opens up a range of possibilities for our platform in precision medicine.

ADCs harness the targeting attributes of antibodies to deliver drugs specifically to the sites of disease.

Our preclinical study has shown the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumours, where they can inhibit tumour growth and improve survival.

Some of the biggest names in pharma are now pursuing opportunities in this space too. Take a look at these recent deals:

Disclaimer

Patrys Limited published this content on 08 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 February 2022 22:50:04 UTC.


© Publicnow 2022
All news about PATRYS LIMITED
06/14Patrys Identifies New Mechanism of Action for Anti-Cancer Antibody
MT
06/03Patrys Secures Grant Funding to Develop Brain Cancer Drug
MT
04/27PATRYS : Appendix 4C - Quarterly - 31 March 2022
PU
04/14PATRYS : Application for quotation of securities - PAB
PU
03/23NEW RESEARCH : Scientists determine structure of a DNA damage ‘First Responder' prot..
PU
02/27Patrys Limited Announces Stable Cell Line for Production of PAT-DX3
CI
02/24PATRYS : Appendix 4D - Half Year Accounts - 31 December 2021
PU
02/24Patrys Limited Reports Earnings Results for the Half Year Ended December 31, 2021
CI
02/07PATRYS : Application for quotation of securities - PAB
PU
02/07PATRYS : ADC Deals Making Headlines
PU
More news
Financials
Sales 2021 1,34 M 0,93 M 0,93 M
Net income 2021 -4,06 M -2,82 M -2,82 M
Net cash 2021 10,9 M 7,58 M 7,58 M
P/E ratio 2021 -22,2x
Yield 2021 -
Capitalization 41,1 M 28,6 M 28,6 M
EV / Sales 2020 11,5x
EV / Sales 2021 67,8x
Nbr of Employees 10
Free-Float 70,9%
Chart PATRYS LIMITED
Duration : Period :
Patrys Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PATRYS LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
James A. Campbell Chief Executive Officer, MD & Director
John Douglas Read Non-Executive Chairman
Valentina Dubljevic Vice President-Scientific & Clinical Development
Michael J. Stork Deputy Chairman & Non-Executive Director
Suzy Jones Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
PATRYS LIMITED-40.54%31
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.64%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-11.36%18 371